$43.86 Million in Sales Expected for Osmotica Pharmaceuticals PLC (NASDAQ:OSMT) This Quarter

Wall Street analysts predict that Osmotica Pharmaceuticals PLC (NASDAQ:OSMT) will post sales of $43.86 million for the current fiscal quarter, according to Zacks Investment Research. Three analysts have issued estimates for Osmotica Pharmaceuticals’ earnings, with the highest sales estimate coming in at $46.70 million and the lowest estimate coming in at $41.90 million. Osmotica Pharmaceuticals posted sales of $57.13 million in the same quarter last year, which indicates a negative year over year growth rate of 23.2%. The firm is expected to report its next quarterly earnings report on Thursday, May 14th.

According to Zacks, analysts expect that Osmotica Pharmaceuticals will report full-year sales of $181.49 million for the current financial year, with estimates ranging from $170.10 million to $194.60 million. For the next financial year, analysts expect that the company will report sales of $204.46 million, with estimates ranging from $183.10 million to $227.68 million. Zacks’ sales averages are a mean average based on a survey of research firms that follow Osmotica Pharmaceuticals.

Osmotica Pharmaceuticals (NASDAQ:OSMT) last announced its earnings results on Wednesday, March 18th. The company reported ($0.51) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.01 by ($0.52). Osmotica Pharmaceuticals had a negative return on equity of 5.97% and a negative net margin of 112.57%. The company had revenue of $59.91 million for the quarter, compared to the consensus estimate of $53.88 million.

A number of research analysts have issued reports on OSMT shares. Zacks Investment Research downgraded shares of Osmotica Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, January 21st. ValuEngine cut shares of Osmotica Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Monday, March 30th. SunTrust Banks started coverage on Osmotica Pharmaceuticals in a report on Wednesday, March 18th. They issued a “buy” rating and a $8.00 price objective for the company. BidaskClub downgraded Osmotica Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Tuesday, February 4th. Finally, SVB Leerink started coverage on Osmotica Pharmaceuticals in a report on Friday, March 6th. They set an “outperform” rating and a $10.00 target price for the company. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $8.36.

In other news, Director Sriram Venkataraman acquired 1,250,000 shares of the firm’s stock in a transaction dated Monday, January 13th. The stock was purchased at an average price of $5.00 per share, for a total transaction of $6,250,000.00. Following the completion of the acquisition, the director now directly owns 22,485,297 shares in the company, valued at approximately $112,426,485. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 4.70% of the company’s stock.

A number of institutional investors have recently made changes to their positions in the stock. Renaissance Technologies LLC grew its holdings in Osmotica Pharmaceuticals by 290.0% during the fourth quarter. Renaissance Technologies LLC now owns 510,112 shares of the company’s stock worth $3,566,000 after buying an additional 379,300 shares in the last quarter. Wedge Capital Management L L P NC grew its holdings in Osmotica Pharmaceuticals by 89.3% during the fourth quarter. Wedge Capital Management L L P NC now owns 203,375 shares of the company’s stock worth $1,422,000 after buying an additional 95,952 shares in the last quarter. Acadian Asset Management LLC grew its holdings in Osmotica Pharmaceuticals by 195.8% during the fourth quarter. Acadian Asset Management LLC now owns 174,295 shares of the company’s stock worth $1,218,000 after buying an additional 115,378 shares in the last quarter. Oxford Asset Management LLP bought a new stake in Osmotica Pharmaceuticals during the fourth quarter worth $1,059,000. Finally, State Street Corp grew its holdings in Osmotica Pharmaceuticals by 20.4% during the fourth quarter. State Street Corp now owns 145,299 shares of the company’s stock worth $1,016,000 after buying an additional 24,617 shares in the last quarter. Institutional investors and hedge funds own 6.81% of the company’s stock.

NASDAQ OSMT traded down $0.09 on Tuesday, hitting $3.04. 125,700 shares of the company were exchanged, compared to its average volume of 354,004. The firm has a 50 day moving average of $4.62 and a two-hundred day moving average of $5.23. The company has a market cap of $151.47 million, a P/E ratio of -0.59 and a beta of 4.18. The company has a current ratio of 2.27, a quick ratio of 1.99 and a debt-to-equity ratio of 2.36. Osmotica Pharmaceuticals has a 1-year low of $2.20 and a 1-year high of $7.97.

Osmotica Pharmaceuticals Company Profile

Osmotica Pharmaceuticals plc, an integrated biopharmaceutical company, develops, manufactures, and commercializes specialty products that target markets with underserved patient populations. The company's promoted approved products include specialty neurology products, such as M-72 to treat ADHD; Osmolex ER for treating Parkinson's and drug-induced extrapyramidal reactions in adults; Lorzone for muscle spasms; ConZip to treat pain; and Ontinua ER for treating opioid withdrawal symptoms.

Read More: Growth Stocks, What They Are, What They Are Not

Get a free copy of the Zacks research report on Osmotica Pharmaceuticals (OSMT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Osmotica Pharmaceuticals (NASDAQ:OSMT)

Receive News & Ratings for Osmotica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Osmotica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.